Amineptine

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 726 Experts worldwide ranked by ideXlab platform

Dominique Pessayre - One of the best experts on this subject based on the ideXlab platform.

  • Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice
    Hepatology, 2003
    Co-Authors: Philippe Letteron, Angela Sutton, Abdellah Mansouri, Bernard Fromenty, Dominique Pessayre
    Abstract:

    Although many steatogenic drugs inhibit mitochondrial fatty acid β-oxidation, limited information is available on possible effects on hepatic lipoprotein secretion. In the endoplasmic reticulum (ER) lumen, microsomal triglyceride transfer protein (MTP) lipidates apolipoprotein B (Apo B), to form triglyceride (TG)-rich very low density lipoprotein (VLDL) particles, which follow vesicular flow to the plasma membrane to be secreted, whereas incompletely lipidated Apo B particles are partly degraded. We studied hepatic MTP activity, the lipoproteins present in the ER lumen, and hepatic lipoprotein secretion 4 hours after administration of a single dose of Amineptine (1 mmol/kg), amiodarone (1 mmol/kg), doxycycline (0.25 mmol/kg), tetracycline (0.25 mmol/kg), tianeptine (0.5 mmol/kg), or pirprofen (2 mmol/kg) in mice. These various doses have been shown previously to markedly inhibit fatty acid oxidation after a single dose, and to trigger steatosis either after repeated doses (doxycycline) or a single dose (other compounds) in mice. In the present study, Amineptine, amiodarone, pirprofen, tetracycline, and tianeptine, but not doxycycline, inhibited MTP activity in vitro, decreased ex vivo MTP activity in the hepatic homogenate of treated mice, decreased TG in the luminal VLDL fraction of hepatic microsomes of treated mice, and decreased in vivo hepatic lipoprotein secretion (TG and Apo B). In conclusion, several steatogenic drugs inhibit not only mitochondrial β-oxidation, as previously shown, but also MTP activity, Apo B lipidation into TG-rich VLDL particles, and hepatic lipoprotein secretion. Drugs with these dual effects may be more steatogenic than drugs acting only on β-oxidation or only MTP. (Hepatology 2003;38:133-140.)

  • Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice
    2003
    Co-Authors: Angela Sutton, Abdellah Mansouri, Bernard Fromenty, Dominique Pessayre
    Abstract:

    Although many steatogenic drugs inhibit mitochondrial fatty acid -oxidation, limited information is available on possible effects on hepatic lipoprotein secretion. In the endo-plasmic reticulum (ER) lumen, microsomal triglyceride transfer protein (MTP) lipidates apolipoprotein B (Apo B), to form triglyceride (TG)-rich very low density lipoprotein (VLDL) particles, which follow vesicular flow to the plasma membrane to be secreted, whereas incompletely lipidated Apo B particles are partly degraded. We studied hepatic MTP activity, the lipoproteins present in the ER lumen, and hepatic lipoprotein secretion 4 hours after administration of a single dose of Amineptine (1 mmol/kg), amiodarone (1 mmol/kg), doxycycline (0.25 mmol/kg), tetracycline (0.25 mmol/kg), tianeptine (0.5 mmol/ kg), or pirprofen (2 mmol/kg) in mice. These various doses have been shown previously to markedly inhibit fatty acid oxidation after a single dose, and to trigger steatosis either after repeated doses (doxycycline) or a single dose (other compounds) in mice. In the present study, Amineptine, amiodarone, pirprofen, tetracycline, and tianeptine, but not doxycycline, inhibited MTP activity in vitro, decreased ex vivo MTP activity in the hepatic homogenate of treated mice, decreased TG in the luminal VLDL fraction of hepatic microsomes of treate

Herrera E Ceballos - One of the best experts on this subject based on the ideXlab platform.

R. Fanelli - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics of Amineptine in man.
    European Journal of Drug Metabolism and Pharmacokinetics, 2016
    Co-Authors: C. Sbarra, M. G. Castelli, A Noseda, R. Fanelli
    Abstract:

    The pharmacokinetics of the new stimulant agent Amineptine has been studied after its oral administration to healthy volunteers. No Statistically significant differences in pharmacokinetic parameters were observed when the drug was administered as capsules or tablets. The pharmacokinetic parameters also showed no change, after a 10-day course of repeated treatment with the drug.

Jaroon Jittiwutikan - One of the best experts on this subject based on the ideXlab platform.

  • Amphetamine Withdrawal: II. A Placebo-Controlled, Randomised, Double-Blind Study of Amineptine Treatment
    Australian & New Zealand Journal of Psychiatry, 1999
    Co-Authors: Manit Srisurapanont, Ngamwong Jarusuraisin, Jaroon Jittiwutikan
    Abstract:

    Objective: The aim of this study was to examine the benefits of Amineptine, a dopamine agonist antidepressant, in treating amphetamine withdrawal.Method: Inpatients with amphetamine withdrawal were recruited to participate in this placebo-controlled, randomised, double-blind, parallel group, 2-week comparison of Amineptine and placebo treatments. The treatment effects were evaluated by means of the self-administered Amphetamine Withdrawal Questionnaire (AWQ) and the interviewer-administered Clinical Global Impression (CGI) scale. An intention-to-treat analysis was applied to evaluate the therapeutic effects at the end of week 1 and week 2.Results: Twenty-two patients took part in each treatment group. The week-1 and week-2 intention-to-treat analyses showed that the mean AWQ reversed vegetative scores (combined scores of decreased energy, increased appetite and craving for sleep items) of the Amineptine group were significantly lower than those of the placebo group. The general condition of the Amineptine...

  • Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1997
    Co-Authors: Jaroon Jittiwutikan, Manit Srisurapanont, Ngamwong Jarusuraisin
    Abstract:

    Temporary inability to function without amphetamine and the experience of withdrawal syndrome enhance the tendency for repetitive use. The investigators proposed to examine the therapeutic effects of Amineptine, an antidepressant with dopamine reuptake inhibition effect, for the treatment of amphetamine withdrawal. The 14-day study was carried out on a randomised, double-blind, placebo-controlled design. The authors assessed the severity of amphetamine withdrawal syndrome by using two measures and performed both end-point and intent-to-treat analyses. The results showed that Amineptine helped relieve a depressed mood within one week and improved the general condition within 2 weeks. In conclusion, Amineptine is effective in rapid relief of depressed mood and improves the general condition of patients with amphetamine withdrawal. Since the amphetamine withdrawal may last for several weeks, studies with longer duration should be conducted before incorporating Amineptine into the clinical practice a of amphetamine withdrawal treatment.

Ngamwong Jarusuraisin - One of the best experts on this subject based on the ideXlab platform.

  • Amphetamine Withdrawal: II. A Placebo-Controlled, Randomised, Double-Blind Study of Amineptine Treatment
    Australian & New Zealand Journal of Psychiatry, 1999
    Co-Authors: Manit Srisurapanont, Ngamwong Jarusuraisin, Jaroon Jittiwutikan
    Abstract:

    Objective: The aim of this study was to examine the benefits of Amineptine, a dopamine agonist antidepressant, in treating amphetamine withdrawal.Method: Inpatients with amphetamine withdrawal were recruited to participate in this placebo-controlled, randomised, double-blind, parallel group, 2-week comparison of Amineptine and placebo treatments. The treatment effects were evaluated by means of the self-administered Amphetamine Withdrawal Questionnaire (AWQ) and the interviewer-administered Clinical Global Impression (CGI) scale. An intention-to-treat analysis was applied to evaluate the therapeutic effects at the end of week 1 and week 2.Results: Twenty-two patients took part in each treatment group. The week-1 and week-2 intention-to-treat analyses showed that the mean AWQ reversed vegetative scores (combined scores of decreased energy, increased appetite and craving for sleep items) of the Amineptine group were significantly lower than those of the placebo group. The general condition of the Amineptine...

  • Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1997
    Co-Authors: Jaroon Jittiwutikan, Manit Srisurapanont, Ngamwong Jarusuraisin
    Abstract:

    Temporary inability to function without amphetamine and the experience of withdrawal syndrome enhance the tendency for repetitive use. The investigators proposed to examine the therapeutic effects of Amineptine, an antidepressant with dopamine reuptake inhibition effect, for the treatment of amphetamine withdrawal. The 14-day study was carried out on a randomised, double-blind, placebo-controlled design. The authors assessed the severity of amphetamine withdrawal syndrome by using two measures and performed both end-point and intent-to-treat analyses. The results showed that Amineptine helped relieve a depressed mood within one week and improved the general condition within 2 weeks. In conclusion, Amineptine is effective in rapid relief of depressed mood and improves the general condition of patients with amphetamine withdrawal. Since the amphetamine withdrawal may last for several weeks, studies with longer duration should be conducted before incorporating Amineptine into the clinical practice a of amphetamine withdrawal treatment.

Related terms

Amineptine - 15 days free trial to Access Experts & Abstracts